NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down‐regulation of the T cell costimulatory molecule CD40 ligand: An open‐label trial

Petros P. Sfikakis, John Boletis, Sophia Lionaki et al. · Arthritis & Rheumatism · 2005 · 411 citations

Quantification of regulatory T cells in patients with systemic lupus erythematosus

José C. Crispín, Jorge Alcocer‐Varela · Journal of Autoimmunity · 2003 · 404 citations

Inflammation, Autoimmune Disease, Systemic Lupus Erythematosus +11

Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE

Therese Vallerskog, Iva Gunnarsson, Mona Widhe et al. · Clinical Immunology · 2006 · 237 citations

Rheumatology, Autoimmune Disease, Allergy +14

Consensus statement on the use of rituximab in patients with rheumatoid arthritis

Josef S Smolen, Edward Keystone, Paul Emery et al. · Annals of the Rheumatic Diseases · 2006 · 224 citations · Full text

Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab

J. A. Bowles, Siao‐Yi Wang, Brian K. Link et al. · Blood · 2006 · 223 citations · Full text

Immunology, Nk Cells, Immunologic Mechanism +16